PMID- 32900505
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 5
DP  - 2020 Nov
TI  - Increased mu-opioid receptor expression is associated with reduced disease-free 
      and overall survival in laryngeal squamous cell carcinoma.
PG  - 722-729
LID - S0007-0912(20)30651-6 [pii]
LID - 10.1016/j.bja.2020.07.051 [doi]
AB  - BACKGROUND: Expression of the mu-opioid receptor (MOR) is associated with poor 
      long-term outcomes in various types of cancer. The association between MOR 
      expression and clinical outcomes in laryngeal squamous cell carcinoma (LSCC) is 
      not clear. METHODS: This retrospective study included patients who underwent 
      laryngectomy for LSCC. The expression pattern of the MOR protein and OPRM1 gene 
      in tumours and corresponding adjacent non-carcinoma specimens was measured. 
      Propensity score matching was used to minimise bias. The primary endpoints were 
      overall survival (OS) and disease-free survival (DFS). The secondary endpoints 
      were intraoperative sufentanil consumption, grade of surgical complications 
      according to the Clavien-Dindo classification, and hospital length of stay. 
      RESULTS: A total of 207 LSCC patients were enrolled. After propensity score 
      matching, there was a significant difference in DFS between groups at 1, 3, and 5 
      yr (60.2% vs 81.2%, P=0.019; 39.4% vs 50.2%, P=0.026; 37.5% vs 42.5%, P=0.023, 
      respectively) in patients with high MOR expression. The OS rates at 1, 3, and 5 
      yr were significantly lower in the high MOR expression group (81.2% vs 93.2%, 
      P=0.027; 57.7% vs 78.3%, P<0.001; 42.5% vs 60.3%, P<0.001, respectively). The 
      multivariate analysis indicated that high MOR expression was associated with 
      worse DFS and OS (hazard ratio: 1.52, 95% confidence interval: 1.07, 2.25, 
      P=0.034; hazard ratio: 1.42, 95% confidence interval: 1.17, 2.34, P=0.032). 
      CONCLUSION: High MOR expression may be associated with poor prognosis in patients 
      with LSCC, suggesting that MOR could be used as a valuable molecular biomarker to 
      predict prognosis of LSCC patients.
CI  - Copyright (c) 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Zhang, Hao
AU  - Zhang H
AD  - Department of Anaesthesiology, Zhongshan Hospital, Fudan University, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China; Department of Anaesthesiology, Sun Yat-sen University Cancer 
      Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation 
      Centre for Cancer Medicine, Guangzhou, China.
FAU - Sun, Minli
AU  - Sun M
AD  - Department of Anaesthesiology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhou, Di
AU  - Zhou D
AD  - Department of Anaesthesiology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Gorur, Aysegul
AU  - Gorur A
AD  - Department of Anaesthesiology and Perioperative Medicine, Anaesthesiology and 
      Surgical Oncology Research Group, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Sun, Zhirong
AU  - Sun Z
AD  - Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China.
FAU - Zeng, Weian
AU  - Zeng W
AD  - Department of Anaesthesiology, Sun Yat-sen University Cancer Centre, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer 
      Medicine, Guangzhou, China.
FAU - Cata, Juan P
AU  - Cata JP
AD  - Department of Anaesthesiology and Perioperative Medicine, Anaesthesiology and 
      Surgical Oncology Research Group, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA. Electronic address: jcata@mdanderson.org.
FAU - Chen, Wankun
AU  - Chen W
AD  - Department of Anaesthesiology, Zhongshan Hospital, Fudan University, Shanghai, 
      China; Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, 
      Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan 
      University, Shanghai, China. Electronic address: chenwank@163.com.
FAU - Miao, Changhong
AU  - Miao C
AD  - Department of Anaesthesiology, Zhongshan Hospital, Fudan University, Shanghai, 
      China. Electronic address: miaochangh@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (OPRM1 protein, human)
RN  - 0 (Receptors, Opioid, mu)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anesthesia
MH  - Carcinoma, Squamous Cell/*genetics/*mortality/surgery
MH  - Disease-Free Survival
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/*mortality/surgery
MH  - Laryngectomy
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Receptors, Opioid, mu/*biosynthesis/genetics
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - OPRM1
OT  - disease-free survival
OT  - laryngeal squamous cell carcinoma
OT  - mu-opioid receptor
OT  - overall survival
EDAT- 2020/09/10 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/09 05:23
PHST- 2020/04/14 00:00 [received]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/09/09 05:23 [entrez]
AID - S0007-0912(20)30651-6 [pii]
AID - 10.1016/j.bja.2020.07.051 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Nov;125(5):722-729. doi: 10.1016/j.bja.2020.07.051. Epub 2020 
      Sep 6.